Cencora, Inc. (COR) To Go Ex-Dividend on August 14th

Cencora, Inc. (NYSE:COR) declared a quarterly dividend on Monday, August 3rd. Investors of record on Friday, August 14th will be given a dividend of 0.60 per share on Monday, August 31st. This represents a c) annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, August 14th.

Cencora has raised its dividend payment by an average of 0.1%annually over the last three years and has increased its dividend annually for the last 15 consecutive years. Cencora has a dividend payout ratio of 13.9% meaning its dividend is sufficiently covered by earnings. Analysts expect Cencora to earn $19.77 per share next year, which means the company should continue to be able to cover its $2.40 annual dividend with an expected future payout ratio of 12.1%.

Cencora Price Performance

Shares of NYSE:COR opened at $333.21 on Wednesday. The company has a quick ratio of 0.58, a current ratio of 0.93 and a debt-to-equity ratio of 3.53. The stock has a market cap of $64.83 billion, a PE ratio of 24.76, a PEG ratio of 1.87 and a beta of 0.57. The company’s fifty day moving average is $296.42 and its 200 day moving average is $313.81. Cencora has a 52 week low of $244.82 and a 52 week high of $377.54.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $4.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.35 by $0.13. Cencora had a net margin of 0.79% and a return on equity of 125.45%. The business had revenue of $84.75 billion during the quarter, compared to analyst estimates of $84.31 billion. During the same period in the prior year, the business posted $4.00 earnings per share. The company’s revenue was up 5.1% on a year-over-year basis. Research analysts anticipate that Cencora will post 17.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

COR has been the topic of several recent research reports. JPMorgan Chase & Co. raised their price target on Cencora from $382.00 to $390.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. UBS Group increased their price objective on Cencora from $412.00 to $430.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Citigroup restated a “buy” rating on shares of Cencora in a research report on Thursday, August 6th. William Blair began coverage on Cencora in a report on Tuesday, April 28th. They issued a “market perform” rating for the company. Finally, Robert W. Baird set a $370.00 price objective on shares of Cencora in a report on Thursday, August 6th. Thirteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $374.25.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.